Everyday Health on MSN

IVIg to SCIg: Considerations when switching immunoglobulin therapies for primary immunodeficiency

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

Hodgkin’s vs. Non-Hodgkin’s Lymphoma: Causes, Symptoms, and Treatment Protocols

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
SciELO

Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials

Background Patients with anti-MAG neuropathy present with distal demyelinating polyneuropathy, IgM monoclonal gammopathy, and elevated titers of anti-MAG antibodies. Objective This paper reviews what ...
The Malaysian Reserve

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Heal…

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

argenx Spotlights VYVGART Sales Surge, First Profitability Year and Expanding Pipeline at JPM Conference

(NASDAQ:ARGX) used its presentation at the 44th JPMorgan Healthcare Conference to highlight what CEO Tim Van Hauwermeiren ...